To further understand how CXCL13 enhances the invasiveness and immune evasion capabilities of melanoma cells, we examined the protein levels in melanoma cells after CXCL13 treatment and observed a significant upregulation of matrix metallopeptidase 9 (MMP9) and programmed death‐ligand 1 (PD‐L1) (Figure 6H). Here, MMP9 is linked to melanoma.